Valuation: Moderna, Inc.

Market Cap 31.65B 27.7B 25.53B 23.66B 44.91B 3,004B 45.64B 306B 119B 1,483B 119B 116B 5,124B P/E 2026 *
-9.21x
P/E 2027 * -16.8x
Enterprise Value 28.25B 24.72B 22.78B 21.11B 40.08B 2,681B 40.73B 273B 106B 1,323B 106B 104B 4,573B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 11.6x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-5.18%
1 week+3.99%
Current month+7.66%
1 month+58.39%
3 months+44.71%
6 months+122.66%
Current year+155.65%
1 week 73.68
Extreme 73.68
85.6
1 month 45.4
Extreme 45.4
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
07-02Fiscal year

Chief Financial Officer

3,607 0.0009%
06-15Fiscal year

Chairperson

160,008 0.0403%
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-5.38%+3.99%+131.69%-38.75% 31.65B
-1.56%+6.71%+21.71%-5.22% 68.8B
-1.65%-3.18%+46.80%+218.33% 55.21B
+1.21%+42.20%+42.20%+42.20% 43.46B
+0.27%+8.33%-49.87%-53.43% 41.18B
-1.32%-3.31%+50.82%-27.98% 30.37B
-0.87%+3.17%+73.52%+89.72% 23.58B
-1.15%+8.29%+4.42%+184.96% 19.33B
-0.81%+3.12%+66.57%+134.22% 17.16B
-0.26%+5.01%+81.19%+350.78% 15.27B
Average -1.12%+4.32%+46.90%+89.48% 34.6B
Weighted average by Cap. -1.13%+4.21%+39.80%+65.33%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.56B 2.97B 199B 3.02B 20.25B 7.87B 98.06B 7.86B 7.69B 339B 2.55B 2.23B 2.06B 1.91B 3.62B 242B 3.68B 24.66B 9.59B 119B 9.57B 9.37B 413B
Net income -3.41B -2.98B -2.75B -2.55B -4.84B -324B -4.92B -32.98B -12.83B -160B -12.8B -12.53B -552B -1.85B -1.62B -1.49B -1.38B -2.63B -176B -2.67B -17.89B -6.96B -86.66B -6.95B -6.8B -300B
Net Debt -3.41B -2.98B -2.75B -2.55B -4.83B -323B -4.91B -32.94B -12.81B -160B -12.79B -12.51B -551B -2.05B -1.8B -1.66B -1.53B -2.91B -195B -2.96B -19.86B -7.72B -96.17B -7.71B -7.54B -332B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
08/07/26 $75.82 -4.96% 1,192,869
07/07/26 $79.77 -2.48% 8,688,340
06/07/26 $81.80 +2.56% 17,296,875
02/07/26 $79.76 +10.01% 14,111,998
01/07/26 $72.50 +3.53% 9,275,292
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
79.77USD
Average target price
47.89USD
Spread / Average Target
-39.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock